Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Voyageur Pharmaceuticals (VM) Stock Price & Analysis

VM Stock Chart & Stats

CA$0.13CA$0.01(4.17%)
At close: 11:01 AM EST
C$0.12C$0.14C$0.1610 Aug24 Aug8 Sep21 Sep5 Oct19 Oct2 Nov
Day’s Range
CAD 0.13 - CAD 0.13
52-Week Range
CAD 0.07 - CAD 0.20
Previous Close
CAD 0.12
Volume
N/A
Average Volume (3M)
132.42K
Market Cap
CAD 27.16M
Enterprise Value
CAD 36.28M
Total Cash (Recent Filing)
CAD 441.87K
Total Debt (Recent Filing)
CAD 40.00K
Price to Earnings (P/E)
―
Beta
0.14
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Early Revenue Growth

Revenue growth of 52.6% shows early commercial traction from a very small base. If the company can sustain this direction while expanding processing and product capabilities, higher sales could gradually improve operating leverage and strengthen its path toward scale.

Low Leverage

Very low debt limits interest obligations and reduces balance-sheet pressure compared with a highly leveraged development company. This provides greater flexibility to allocate capital toward projects and operations, although future funding needs could still affect shareholders.

Specialized Healthcare Positioning

A focused offering in pharmaceutical-grade barium sulfate and imaging contrast materials gives the company a defined healthcare-oriented niche. Exposure to medical imaging and related industrial applications could support a durable market opportunity if development and manufacturing efforts succeed.

Bears Say

Severe Unprofitability

Large gross and net losses show that the current revenue base is far below the cost structure required to operate the business. Until sales expand materially or expenses decline, profitability remains distant and the company has limited evidence of a sustainable earnings model.

Persistent Cash Burn

Negative operating and free cash flow indicate that operations continue to consume cash rather than fund themselves. Ongoing burn can force the company to seek additional capital, potentially limiting strategic flexibility and creating continuing financing pressure over the next several quarters.

Eroding Shareholder Equity

The substantial decline in equity indicates that ongoing losses are reducing the capital base available to support development. Continued erosion may increase dependence on external financing and could constrain the company’s ability to pursue projects without further shareholder dilution.

Voyageur Pharmaceuticals News

VM FAQ

What was Voyageur Pharmaceuticals’s price range in the past 12 months?
Voyageur Pharmaceuticals lowest stock price was C$0.07 and its highest was C$0.20 in the past 12 months.
What is Voyageur Pharmaceuticals’s market cap?
Voyageur Pharmaceuticals’s market cap is C$27.16M.
When is Voyageur Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Voyageur Pharmaceuticals’s earnings last quarter?
Voyageur Pharmaceuticals released its earnings results on Oct 30, 2026. The company reported -C$0.003 earnings per share for the quarter.
Is Voyageur Pharmaceuticals overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Voyageur Pharmaceuticals pay dividends?
Voyageur Pharmaceuticals does not currently pay dividends.
What is Voyageur Pharmaceuticals’s EPS estimate?
Voyageur Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Voyageur Pharmaceuticals have?
Voyageur Pharmaceuticals has 226,342,350 shares outstanding.
What happened to Voyageur Pharmaceuticals’s price movement after its last earnings report?
Voyageur Pharmaceuticals reported an EPS of -C$0.003 in its last earnings report. Following the earnings report the stock price went up 4.167%.
Which hedge fund is a major shareholder of Voyageur Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:VM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology